Obesity and prostate cancer: Weighing the evidence

European Urology

Volumn 63, Issue 5, 2013, Pages 800-809

  Allott, Emma H ^a   Masko, Elizabeth M ^a   Freedland, Stephen J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Estrogen; Insulin; Obesity; Prostate cancer; Review; Testosterone; Weight change

Indexed keywords

ADIPONECTIN; ANDROGEN; ESTRADIOL; INTERLEUKIN 6; LEPTIN; SILTUXIMAB; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; AROMATIZATION; BODY MASS; BRACHYTHERAPY; CALORIC RESTRICTION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; DELAYED DIAGNOSIS; DISEASE COURSE; DOSE RESPONSE; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; GENETIC RISK; GENETIC VARIABILITY; GLEASON SCORE; HUMAN; HYPERINSULINEMIA; IMMOBILIZATION; INTESTINE FUNCTION; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; SYSTEMATIC REVIEW (TOPIC); TUMOR VASCULARIZATION; UPREGULATION; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; BRACHYTHERAPY; CALORIC RESTRICTION; EXERCISE; HUMANS; MALE; OBESITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING; WEIGHT LOSS;

EID: 84876059411     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.11.013     Document Type: Review

References (98)

1. M.M. Center, A. Jemal, and J. Lortet-Tieulent International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
2. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, and M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 2003 1625 1638
3. G.K. Reeves, K. Pirie, and V. Beral Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study BMJ 335 2007 1134
4. A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, and M. Zwahlen Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies Lancet 371 2008 569 578
5. K.M. Flegal, M.D. Carroll, C.L. Ogden, and L.R. Curtin Prevalence and trends in obesity among US adults, 1999-2008 JAMA 303 2010 235 241
6. A. Berghofer, T. Pischon, and T. Reinhold Obesity prevalence from a European perspective: a systematic review BMC Public Health 8 2008 200
7. E.M. Masko, E.H. Allott, and S.J. Freedland The relationship between nutrition and prostate cancer: is more always better? Eur Urol 63 2013 810 820
8. W.C. Buschemeyer III, and S.J. Freedland Obesity and prostate cancer: epidemiology and clinical implications Eur Urol 52 2007 331 343
9. R.J. MacInnis, and D.R. English Body size and composition and prostate cancer risk: systematic review and meta-regression analysis Cancer Causes Control 17 2006 989 1003
10. A. Bergstrom, P. Pisani, V. Tenet, A. Wolk, and H.O. Adami Overweight as an avoidable cause of cancer in Europe Int J Cancer 91 2001 421 430
11. J. Baillargeon, E.A. Platz, and D.P. Rose Obesity, adipokines, and prostate cancer in a prospective population-based study Cancer Epidemiol Biomarkers Prev 15 2006 1331 1335
12. A. Engeland, S. Tretli, and T. Bjorge Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men Br J Cancer 89 2003 1237 1242
13. S.O. Andersson, A. Wolk, and R. Bergstrom Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers J Natl Cancer Inst 89 1997 385 389
14. M.P. Porter, and J.L. Stanford Obesity and the risk of prostate cancer Prostate 62 2005 316 321
15. Z. Gong, M.L. Neuhouser, and P.J. Goodman Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial Cancer Epidemiol Biomarkers Prev 15 2006 1977 1983
16. C. Rodriguez, S.J. Freedland, and A. Deka Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort Cancer Epidemiol Biomarkers Prev 16 2007 63 69
17. M.E. Wright, S.C. Chang, and A. Schatzkin Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality Cancer 109 2007 675 684
18. L.L. Banez, R.J. Hamilton, and A.W. Partin Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer JAMA 298 2007 2275 2280
19. A. Discacciati, N. Orsini, and A. Wolk Body mass index and incidence of localized and advanced prostate cancer - a dose-response meta-analysis of prospective studies Ann Oncol 23 2012 1665 1671
20. I.A. Hekal, and E.I. Ibrahiem Obesity-PSA relationship: a new formula Prostate Cancer Prostatic Dis 13 2010 186 190
21. J. Baillargeon, B.H. Pollock, and A.R. Kristal The association of body mass index and prostate-specific antigen in a population-based study Cancer 103 2005 1092 1095
22. R.L. Grubb, A. Black, and G. Izmirlian Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cancer Epidemiol Biomarkers Prev 18 2009 748 751
23. D.I. Chu, C. De Nunzio, and L. Gerber Predictive value of digital rectal examination for prostate cancer detection is modified by obesity Prostate Cancer Prostatic Dis 14 2011 346 353
24. S.J. Freedland, E.A. Platz, and J.C. Presti Jr. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection J Urol 175 2006 500 504
25. C. Rodriguez, A.V. Patel, and E.E. Calle Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States Cancer Epidemiol Biomarkers Prev 10 2001 345 353
26. Y. Cao, and J. Ma Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis Cancer Prev Res (Phila) 4 2011 486 501
27. S.J. Freedland, L. Sun, and C.J. Kane Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases BJU Int 102 2008 969 974
28. S.J. Freedland, K.A. Grubb, and S.K. Yiu Obesity and capsular incision at the time of open retropubic radical prostatectomy J Urol 174 2005 1798 1801
29. O.T. Okotie, W.J. Aronson, and J.A. Wieder Predictors of metastatic disease in men with biochemical failure following radical prostatectomy J Urol 171 2004 2260 2264
30. J.R. Wong, Z. Gao, and S. Merrick Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images Int J Radiat Oncol Biol Phys 75 2009 49 55
31. L.E. Millender, M. Aubin, J. Pouliot, K. Shinohara, and M. Roach III Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 59 2004 6 10
32. G.S. Merrick, R.W. Galbreath, and W.M. Butler Obesity is not predictive of overall survival following permanent prostate brachytherapy Am J Clin Oncol 30 2007 588 596
33. C.J. Keto, W.J. Aronson, and M.K. Terris Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database BJU Int 110 2011 492 498
34. M.R. Smith Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer Clin Cancer Res 13 2007 241 245
35. I.H. Derweesh, C.J. Diblasio, and M.C. Kincade Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer BJU Int 100 2007 1060 1065
36. G. Ploussard, A. de la Taille, and Y. Bayoud The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance Eur Urol 61 2012 356 362
37. K.Y. Wolin, J. Luly, S. Sutcliffe, G.L. Andriole, and A.S. Kibel Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity J Urol 183 2010 629 633
38. S.J. Freedland, M.C. Haffner, P.K. Landis, C.S. Saigal, and H.B. Carter Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy Urology 65 2005 1131 1136
39. J.S. Montgomery, B.A. Gayed, and B.K. Hollenbeck Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy J Urol 176 2006 257 261
40. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261
41. E.E. Uffort, and J.C. Jensen Impact of obesity on early erectile function recovery after robotic radical prostatectomy JSLS 15 2011 32 37
42. S.M. Collin, R.M. Martin, and C. Metcalfe Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study Lancet Oncol 9 2008 445 452
43. M.D. Fesinmeyer, R. Gulati, and S. Zeliadt Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States Cancer Epidemiol Biomarkers Prev 18 2009 808 815
44. D.L. Roberts, C. Dive, and A.G. Renehan Biological mechanisms linking obesity and cancer risk: new perspectives Annu Rev Med 61 2010 301 316
45. S. Sharad, A. Srivastava, and S. Ravulapalli Prostate cancer gene expression signature of patients with high body mass index Prostate Cancer Prostatic Dis 14 2011 22 29
46. V. Venkateswaran, A.Q. Haddad, and N.E. Fleshner Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts J Natl Cancer Inst 99 2007 1793 1800
47. S.J. Freedland, J. Mavropoulos, and A. Wang Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis Prostate 68 2008 11 19
48. M.E. Cox, M.E. Gleave, and M. Zakikhani Insulin receptor expression by human prostate cancers Prostate 69 2009 33 40
49. J. Ma, H. Li, and E. Giovannucci Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis Lancet Oncol 9 2008 1039 1047
50. J.L. Wright, and J.L. Stanford Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study Cancer Causes Control 20 2009 1617 1622
51. A. Decensi, M. Puntoni, and P. Goodwin Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis Cancer Prev Res (Phila) 3 2010 1451 1461
52. J.S. Kasper, Y. Liu, and E. Giovannucci Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study Int J Cancer 124 2009 1398 1403
53. A.G. Renehan, M. Zwahlen, and C. Minder Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis Lancet 363 2004 1346 1353
54. M.A. Rowlands, D. Gunnell, and R. Harris Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis Int J Cancer 124 2009 2416 2429
55. M.A. Rowlands, J.M. Holly, and D. Gunnell Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT Cancer Res 72 2012 503 515
56. T. Nickerson, F. Chang, and D. Lorimer In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR) Cancer Res 61 2001 6276 6280
57. G. Williams Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-alpha and GPER signalling Mol Cell Endocrinol 351 2012 269 278
58. A.W. Roddam, N.E. Allen, P. Appleby, and T.J. Key Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 2008 170 183
59. Schnoeller T, Jentzmik F, Rinnab L, et al. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol. In press. http://dx.doi.org/10.1007/ s00345-012-0902-5.
60. A. Morgentaler Testosterone and prostate cancer: an historical perspective on a modern myth Eur Urol 50 2006 935 939
61. M.R. Theoret, Y.M. Ning, and J.J. Zhang The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention N Engl J Med 365 2011 97 99
62. G. Carruba Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario J Cell Biochem 102 2007 899 911
63. S. Yao, C. Till, and A.R. Kristal Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study Cancer Causes Control 22 2011 1121 1131
64. H. Bonkhoff, and R. Berges The evolving role of oestrogens and their receptors in the development and progression of prostate cancer Eur Urol 55 2009 533 542
65. P. Somasundar, K.A. Frankenberry, and H. Skinner Prostate cancer cell proliferation is influenced by leptin J Surg Res 118 2004 71 82
66. M.R. Hoda, and G. Popken Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells BJU Int 102 2008 383 388
67. C.Y. Huang, H.S. Yu, and T.Y. Lai Leptin increases motility and integrin up-regulation in human prostate cancer cells J Cell Physiol 226 2011 1274 1282
68. S.J. Freedland, L.J. Sokoll, and L.A. Mangold Serum leptin and pathological findings at the time of radical prostatectomy J Urol 173 2005 773 776
69. H. Li, M.J. Stampfer, and L. Mucci A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival Clin Chem 56 2010 34 43
70. S. Goktas, M.I. Yilmaz, and K. Caglar Prostate cancer and adiponectin Urology 65 2005 1168 1172
71. M. Okamoto, C. Lee, and R. Oyasu Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro Cancer Res 57 1997 141 146
72. A. Azevedo, V. Cunha, A.L. Teixeira, and R. Medeiros IL-6/IL-6R as a potential key signaling pathway in prostate cancer development World J Clin Oncol 2 2011 384 396
73. S.F. Shariat, B. Andrews, and M.W. Kattan Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis Urology 58 2001 1008 1015
74. V. Michalaki, K. Syrigos, P. Charles, and J. Waxman Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer Br J Cancer 90 2004 2312 2316
75. J.R. Stark, H. Li, and P. Kraft Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality Int J Cancer 124 2009 2683 2689
76. D. Il'yasova, L.H. Colbert, and T.B. Harris Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort Cancer Epidemiol Biomarkers Prev 14 2005 2413 2418
77. K. Heikkila, R. Harris, and G. Lowe Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis Cancer Causes Control 20 2009 15 26
78. K. Fizazi, J.S. De Bono, and A. Flechon Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer Eur J Cancer 48 2012 85 93
79. J.Y. Chun, N. Nadiminty, and S. Dutt Interleukin-6 regulates androgen synthesis in prostate cancer cells Clin Cancer Res 15 2009 4815 4822
80. A. Hobisch, I.E. Eder, and T. Putz Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor Cancer Res 58 1998 4640 4645
81. A.A. Lubik, J.H. Gunter, and S.C. Hendy Insulin increases de novo steroidogenesis in prostate cancer cells Cancer Res 71 2011 5754 5764
82. S.C. Moore, M.F. Leitzmann, and D. Albanes Adipokine genes and prostate cancer risk Int J Cancer 124 2008 869 876
83. R. Ribeiro, C. Monteiro, and V. Catalan Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue BMC Med 10 2012 108
84. J.G. van Roermund, K.A. Hinnen, and C.J. Tolman Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients BJU Int 107 2011 1775 1779
85. D.S. Finley, V.S. Calvert, and J. Inokuchi Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness J Urol 182 2009 1621 1627
86. R.J. Ribeiro, C.P. Monteiro, and V.F. Cunha Tumor cell-educated periprostatic adipose tissue acquires an aggressive cancer-promoting secretory profile Cell Physiol Biochem 29 2012 233 240
87. M.J. Bonorden, O.P. Rogozina, and C.M. Kluczny Intermittent calorie restriction delays prostate tumor detection and increases survival time in TRAMP mice Nutr Cancer 61 2009 265 275
88. J. Blando, T. Moore, and S. Hursting Dietary energy balance modulates prostate cancer progression in Hi-Myc mice Cancer Prev Res (Phila) 4 2011 2002 2014
89. J.K. Bassett, G. Severi, and L. Baglietto Weight change and prostate cancer incidence and mortality Int J Cancer 131 2011 1711 1719
90. B.M. Whitley, D.M. Moreira, and J.A. Thomas Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database Prostate Cancer Prostatic Dis 14 2011 361 366
91. C.E. Joshu, A.M. Mondul, and A. Menke Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era Cancer Prev Res (Phila) 4 2011 544 551
92. C. Chamberlain, P. Romundstad, L. Vatten, D. Gunnell, and R.M. Martin The association of weight gain during adulthood with prostate cancer incidence and survival: a population-based cohort Int J Cancer 129 2011 1199 1206
93. A.V. Patel, C. Rodriguez, and E.J. Jacobs Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men Cancer Epidemiol Biomarkers Prev 14 2005 275 279
94. N.F. Johnsen, A. Tjonneland, and B.L. Thomsen Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort Int J Cancer 125 2009 902 908
95. T.I. Nilsen, P.R. Romundstad, and L.J. Vatten Recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study) Int J Cancer 119 2006 2943 2947
96. S.A. Kenfield, M.J. Stampfer, E. Giovannucci, and J.M. Chan Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study J Clin Oncol 29 2011 726 732
97. Y. Liu, F. Hu, and D. Li Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis Eur Urol 60 2011 1029 1044
98. L.W. Jones, J. Antonelli, and E.M. Masko Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer J Appl Physiol 113 2012 263 272